In short-term studies, once weekly and twice weekly dosing regimens of eryt
hropoietin (EPO) have both been shown to be effective in correcting anaemia
in dialysis patients. However, the optimal dosing frequency has yet to be
determined. The long-term effects of EPO given by more frequent divided dos
es in 10 stable haemodialysis patients were studied. The patients achieved
a stable haemoglobin level for at least 3 months prior to the study. The fr
equency of administration was altered from 4000 units once weekly to 2000 u
nits twice weekly in seven patients, from 4000 units once every 10 days to
2000 units twice weekly alternating with 2000 units once weekly in two pati
ents, and from 4000 units fortnightly to 2000 units once weekly in one pati
ent. After the conversion, EPO dosage was adjusted in order to maintain the
haemoglobin at the preconversion level. At the end of 28 weeks, the mean h
aemoglobin level remained unchanged, However, the mean dosage requirement o
f EPO reduced from 3400 units per week to 2500 units per week (P = 0.019),
This represents a significant 26% reduction in dosage and cost. It was conc
luded that subcutaneous administration of frequent small doses of EPO is a
more cost-effective way of correcting anaemia in haemodialysis patients.